Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.
Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...
Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
Dexamphetamine – a restricted stimulant drug used to treat narcolepsy and Attention Deficient Hyperactivity Disorder (ADHD) – might not be as addictive as previously thought, new research from the ...
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.
Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...
News Medical on MSN2d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugsObesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
One of the most exciting developments in diabetes treatment is the use of new medications that help control blood sugar in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback